Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tasadenoturev,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2 multicenter CAPTIVE study is evaluating DNX-2401 (tasadenoturev), DNAtrix's adenovirus-based immunotherapy, in combination with pembrolizumab for the treatment of GBM at first or second recurrence. Data from 49 patients will be presented.
Product Name : DNX-2401
Product Type : Microorganism
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : Tasadenoturev,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable